J&J’s Topamax Cleared For Seizure Monotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson subsidiary Ortho-McNeil's anti-convulsant Topamax (topiramate) cleared FDA June 29 for the supplemental indication of initial monotherapy for seizures
You may also be interested in...
J&J Topamax Successor Could Be Ready By 2009
J&J identifies RWJ-333369 as potential follow-on to Topamax, and plans to accelerate development ahead of expected topiramate generic entry in 2009. Phase IIb data will be available by end of 2005.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.